First Canadian patient dosed in cell therapy trial for corneal edema
Key takeaways:
- The study will evaluate three different doses of neltependocel.
- Approximately 100 patients will be included in the study.
The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.
The drug, AURN001 (Aurion Biotech), is a combination cell therapy that consists of neltependocel and Y-27632, according to a press release. AURN001 is intended to be administered to the eye as a one-time intracameral injection.
Image: Adobe Stock
Approximately 100 patients will be included in the ABA-1/CLARA study, which is designed to examine three different doses of neltependocel used in combination with Y-27632, according to the release.
“We know that corneal dystrophies such as Fuchs’ affect about 4% of eyes over the age of 40,” Aurion CEO Greg Kunst told Healio in an email. “We hope that the outcomes from our ABA-1/CLARA trial will contribute meaningful insights to the treatment of this sight-threatening condition.”
Collapse
Read more about